Last reviewed · How we verify

NCT04260893: DED

Prospective Study To Assess The Safety And Effectiveness Of Tixel Treatment On Dry Eye Symptoms In Asian Patients

Terminated NA Last updated 7 May 2021
What this trial tests

NA trial testing Tixel in Dry Eye Syndromes in 44 participants. Terminated before completion.

Timeline
23 January 2020
Primary endpoint
13 March 2021
13 March 2021

Quick facts

Lead sponsorNovoxel Ltd.
PhaseNA
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment44
Start date23 January 2020
Primary completion13 March 2021
Estimated completion13 March 2021
Sites1 location across Cambodia

Drugs / interventions tested

Conditions studied

Sponsor

Novoxel Ltd.

Who can join

18 and older, any sex, with Dry Eye Syndromes or Dry Eye. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Pilot study where effect of standard Tixel treatment as used for periorbital wrinkles would be assessed on Dry Eye Disease symptoms and signs in Asian Patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Tixel

Trials testing the same drug.

Other recruiting trials for Dry Eye Syndromes

Currently open trials in the same condition.

Other Novoxel Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04260893.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing